Lukaszuk Krzysztof, Podolak Amira, Malinowska Paulina, Lukaszuk Jakub, Jakiel Grzegorz
Invicta Research and Development Center, Polna 64, 81-740 Sopot, Poland.
Department of Obstetrics and Gynecological Nursing, Faculty of Health Sciences, Medical University of Gdansk, 80-210 Gdansk, Poland.
Vaccines (Basel). 2022 Mar 27;10(4):521. doi: 10.3390/vaccines10040521.
Media reports have caused a significant drop in confidence in the AstraZeneca ChAdOx1 nCoV-19 COVID-19 vector vaccine (Vaxzevria, AstraZeneca Södertälje, Sweden). This has caused many people, already vaccinated with the first dose of AstraZeneca, to refuse vaccination with this product. On the other hand, the increased demand for mRNA vaccines has resulted in a greater shortage of mRNA vaccines and cases of people being vaccinated with the AstraZeneca vaccine after the first dose of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine (Comirnaty, Pfizer/BioNTech, Mainz, Germany). Moreover, currently, 60.9% of the global population have received at least one dose of a COVID-19 vaccine, while only 10% of people in low-income countries have received at least one dose. Even less people are fully vaccinated. The present pilot study evaluated the administration of half doses of AstraZeneca and Pfizer vaccines and included the enrollment of 26 subjects who were vaccinated with a different vaccine the first and second time. The reference group included individuals undergoing vaccination with two full doses of the Pfizer vaccine (21-day interval) monitored for their antibody levels as part of a parallel study. The distribution of antibody levels was not significantly different between those who received the Pfizer vaccine alone and those receiving the AstraZeneca vaccine plus Pfizer or Pfizer and AstraZeneca. To prepare for the next pandemic waves, solving the problem of the matching of booster vaccine to the previously received doses would be advisable. The topic is important and emerging as most of the population in low-income countries is still not vaccinated. We strongly believe that vaccine equity is the most important aspect of vaccination strategies.
媒体报道已导致对阿斯利康ChAdOx1 nCoV-19新冠病毒载体疫苗（Vaxzevria，瑞典阿斯利康公司，南泰利耶）的信心大幅下降。这使得许多已经接种了第一剂阿斯利康疫苗的人拒绝接种该产品。另一方面，对mRNA疫苗需求的增加导致mRNA疫苗更加短缺，以及一些人在接种了辉瑞/ BioNTech的BNT162b2新冠疫苗（Comirnaty，德国美因茨辉瑞/ BioNTech公司）第一剂后接种了阿斯利康疫苗的情况。此外，目前全球60.9%的人口已接种至少一剂新冠疫苗，而低收入国家只有10%的人接种了至少一剂。完全接种疫苗的人更少。本试点研究评估了阿斯利康和辉瑞疫苗半剂量的接种情况，纳入了26名在第一次和第二次接种时接种不同疫苗的受试者。作为一项平行研究的一部分，参考组包括接受两剂完整辉瑞疫苗（间隔21天）接种并监测其抗体水平的个体。单独接种辉瑞疫苗的人与接种阿斯利康疫苗加辉瑞或辉瑞加阿斯利康疫苗的人之间抗体水平分布没有显著差异。为应对下一波疫情，解决加强疫苗与先前接种剂量匹配的问题是可取的。鉴于低收入国家的大多数人口仍未接种疫苗，这个话题很重要且正在兴起。我们坚信疫苗公平是疫苗接种策略中最重要的方面。
